118 Chapter 6 REFERENCES 1. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12: 1935-1939. 2. Darby SC, Sau WK, Spooner RJ, Giangrande PLF, Hill FGH, Hay CRM, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007; 110: 815-825. 3. van Vulpen LFD, Holstein K, Martinoli C. Joint disease in haemophilia: Pathophysiology, pain and imaging. Haemophilia. 2018; 24: 44-49. 4. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni M V., Windyga J, Llinás A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26:1-158. 5. Mannucci PM, Tuddenham EGD. The Hemophilias — From Royal Genes to Gene Therapy. New N Engl J Med. 2002; 344: 1773-1779. 6. Ay C, Perschy L, Rejtö J, Kaider A, Pabinger I. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. Ann Hematol. 2020; 99: 2763-2771. 7. Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S, Talks K, Tunstall O, Biss T. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020; 90: 684-695. 8. Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Álvarez-Román MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmström M, Schved JF, Trossaërt M, Hermans C, Boban A, Ludlam C, Lethagen S. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017; 23: 105-114. 9. Beeton K, Neal D, Watson T, Lee CA. Parents of children with haemophilia - A transforming experience. Haemophilia. 2007; 13: 570-579. 10. Van Den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E, Ljung R. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019; 134: 317-320. 11. Rodriguez-Merchan EC, Valentino LA. Emicizumab: Review of the literature and critical appraisal. Haemophilia. 2019; 25: 11-20. 12. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) from European Medicines Agency (EMA). Assessment Report - Emicizumab (Hemlibra). EMA/125963/2019. Accessed 31 Jan 2019. 13. European Medicines Agency. Hemlibra (emicizumab) Summary of Product Characteristics. 2018. https:// www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf. Accessed on 08-10-2021. 14. Powell JR, Cook J, Wang Y, Peck R, Weiner D. Drug Dosing Recommendations for All Patients: A Roadmap for Change. Clin Pharmacol Ther. 2021; 109: 65-72. 15. Atkinson AJ, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: A historical overview. Clin Pharmacol Ther. 2007; 82: 3-6.
RkJQdWJsaXNoZXIy MTk4NDMw